Concord Biotech Limited announced the successful conclusion of a U.S. Food and Drug Administration (USFDA) inspection at its Unit II formulation facility in Valthera, Gujarat. The inspection, completed on September 18, 2026, resulted in one minor procedural observation unrelated to Good Manufacturing Practices (GMP). The company expects no material impact on its business operations and will provide a comprehensive response to the observation within the stipulated timeline.
USFDA Inspection Concludes at Valthera Facility
Concord Biotech Limited has formally notified stakeholders regarding the outcome of a recent inspection conducted by the U.S. Food and Drug Administration (USFDA). The inspection took place at the company’s formulation facility located at Unit II, Plot No. 297-298/2p, At. Valthera, Tal. Dholka, Dist. Ahmedabad, Gujarat. The inspection was successfully completed on September 18, 2026.
Key Findings and Future Actions
At the conclusion of the inspection, the USFDA issued one minor observation. Crucially, this observation is purely procedural in nature and is not related to Good Manufacturing Practices (GMP). Concord Biotech has stated that this development is not expected to have any material impact on the company’s current business operations or its existing supplies originating from this facility. The company is committed to submitting a comprehensive response to the observation within the timeframe specified by the regulatory authority.
Regulatory Disclosure Compliance
This disclosure is made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The requisite details as per the provisions of Regulation 30, read with Schedule III and relevant SEBI Master Circulars, including those dated November 11, 2024, and updated on January 30, 2026, are enclosed for information and record purposes.
Source: BSE
